compound 5i [PMID: 36542759]   Click here for help

GtoPdb Ligand ID: 12336

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This compound is an orally bioavailable macrocyclic inhibitor of hematopoietic progenitor kinase 1 (HPK1; MAP4K1) [3]. It reverses the negative regulatory effect of HPK1 on T-cell activation. Compound 5i synergises with anti-PD-1 checkpoint inhibition in mouse tumour models, which is suggestive of potential as an adjunct in cancer immunotherapy.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 4
Topological polar surface area 141.14
Molecular weight 539.26
XLogP 4.54
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC[C@H]1Nc2nc(ncc2c2cnn(c2)CC(O)(C)C)Nc2ccc(c(c2)CCCCOc2c1cccc2)C#N
Isomeric SMILES OC[C@H]1Nc2c(cnc(Nc3cc(CCCCOc4c1cccc4)c(cc3)C#N)n2)c1cn(CC(C)(O)C)nc1
InChI InChI=1S/C30H33N7O3/c1-30(2,39)19-37-17-22(15-33-37)25-16-32-29-34-23-11-10-21(14-31)20(13-23)7-5-6-12-40-27-9-4-3-8-24(27)26(18-38)35-28(25)36-29/h3-4,8-11,13,15-17,26,38-39H,5-7,12,18-19H2,1-2H3,(H2,32,34,35,36)/t26-/m1/s1
InChI Key DSSNAGYVGTYAGH-AREMUKBSSA-N
Immunopharmacology Comments
HPK1 (MAP4K1) is a negative regulator of T cell activation and proliferation, via both a destabilising effect on the TCR signalling complex [4], and modulation of PGE2-mediated gene transcription [1-2].